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Summary
Heart failure is a term used to define a constellation 
of symptoms and signs that are commonly attributed 
to the inability of the heart to produce a cardiac out-
put that meets the demands of the body. It remains a 
deadly disease, affecting between 1-2% of the popu-
lation, and is more common in the elderly, with around 
6-10% of patients over 65 suffering from the condi-
tion. Sacubitril/valsartan (LCZ-696) is a combined 
neprilysin inhibitor and angiotensin AT1 receptor 
blocker approved in recent years for the treatment of 
chronic heart failure with reduced ejection fraction. 
In an area where there have been limited pharmaco-
logical advances in the last 10 years, this drug was 
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a game changer and a much welcomed addition to 
contemporary heart failure therapy. It is currently 
being studied in patients with heart failure with 
preserved ejection fraction and for the reduction of 
heart failure events post-acute myocardial infarc-
tion. Results from the ongoing PARADISE-MI study 
are awaited by the global cardiology community 
with great interest.
Key words: Sacubitril/valsartan – LCZ-696 – Heart 
failure – Myocardial infarction
Background
Heart failure is a term used to define a constellation 
of symptoms and signs that are commonly attributed 
to the inability of the heart to produce a cardiac out-
put that meets the demands of the body� Exertional 
dyspnea, peripheral edema as well as orthopnea 
are the usual findings following history taking and 
physical examination� It remains a deadly disease 
and increasingly effective treatments in modern day 
medicine mean that patients are living longer and 
are more likely to have multiple comorbidities when 
they present to hospital� It affects between 1-2% of 
the population and is more common in the elderly; 
around 6-10% of patients over 65 years of age suffer 
from the condition (1)�
The term “heart failure with reduced ejection frac-
tion” and “heart failure with preserved ejection 
fraction” describe two completely different diseases 
and underlying pathophysiology� Around 50% of 
patients with heart failure have preserved ejection 
fraction� However, in day to day clinical practice, 
unless explicitly stated otherwise, the use of the 
term heart failure is commonly understood to refer 
to heart failure with reduced ejection fraction� The 
reduction in systolic function of the left ventricle 
commonly results from a variety of causes� This 
is also dependent on geographical location and 
prevalence of other environmental risks such as 
communicable diseases, malnutrition and low 
socioeconomic status� In North America and Western 
Europe, coronary artery disease remains the big-
gest underlying cause of heart failure with reduced 
ejection fraction (HFrEF)� While in Africa and Asia, 
rheumatic heart disease is still a major cause, simi-
lar to the role played by hypertension in the African-
American cohort (2)�
Physiological Consequences of  
Heart Failure
A reduction in ejection fraction activates a sequence 
of adaptive mechanisms to maintain adequate car-
diac output� The renin–angiotensin–aldosterone 
system (RAAS) as well as the adrenergic system are 
activated which leads to increased left ventricular 
contractility and vasoconstriction� The resulting 
increase in sodium and water retention, heart rate 
and blood pressure synergistically aim to maintain 
adequate cardiac output� Although this neuroen-
docrine activation initially aims to meet cardiac 
output demand, continuous activation results in 
maladaptive cardiac remodeling and has deleteri-
ous effects on left ventricular function (3)� The cir-
culating levels of angiotensin-2 (Ang II) have been 
shown to increase in heart failure, impacting on cell 
function and altering intrinsic myocardial contrac-
tility, ventricular stiffness and diastolic function (4)� 
Meanwhile, continuous sympathetic drive has been 
shown to result in eccentric left ventricular hypertro-
phy, maladaptive remodeling and worsening heart 
failure (4)� High circulating aldosterone levels were 
found to have an impact on cardiac function� This 
occurs through mechanisms such as magnesium/
potassium loss, sympathetic activation, parasympa-
thetic inhibition and also myocardial fibrosis (5, 6)�
Contemporary Heart Failure Therapy
Based on the above hypotheses, multiple random-
ized controlled trials have been conducted over 
the last three decades to investigate and establish 
treatment for heart failure� Blockade of the adren-
ergic, as well as the RAAS, formed the basis of ther-
apy� β-Blockers have been shown in trials such as 
CIBIS-II, COPERNICUS and MERIT-HF to reduce mor-
tality by up to a third (7-9)�
Almost a decade earlier, CONSENSUS and SOLVD 
investigators also confirmed the mortality benefit 
of angiotensin-converting enzyme (ACE) inhibitors 
when added to standard heart failure therapy (10, 11)�
Despite treatment with ACE inhibitors and the prog-
ress that was made, mortality from heart failure 
remained high� The concept of “aldosterone escape” 
led researchers to test the hypothesis of aldosterone 
antagonists to improve heart failure mortality (12)� 
This led to the design of the RALES trial which sought 
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to answer this question with the drug spironolac-
tone� The trial was stopped early due to marked 
mortality benefit in the spironolactone arm (13)�
The Role of Natriuretic Peptide and 
Neprilysin Inhibition
The natriuretic peptide system counteracts the 
effects of RAAS activation, inhibits secretion of argi-
nine vasopressin and modulates the autonomic 
nervous system (14)� The release of brain natriuretic 
peptide (BNP) and N-terminal proBNP (NT-proBNP) 
promotes natriuresis and vasodilatation and occurs 
as a response to the resulting increase in ventricu-
lar preload and afterload seen in heart failure (14)� 
In the atrium, atrial natriuretic peptide (ANP) is also 
released as a response to atrial stretch and plays a 
similar role to BNP and NT-proBNP�
Naturally, efforts have been made to try and manipulate 
this pathway to improve heart failure outcomes� Initial 
strategies have focused on two aspects: the adminis-
tration of exogenous natriuretic peptide as well as the 
inhibition of its breakdown� BNP and NT-proBNP are 
broken down by neprilysin, a membrane bound endo-
peptidase� Disappointingly, the administration of the 
recombinant BNP nesiritide in the ASCEND-HF study, 
which was a large randomized, double-blind, placebo- 
controlled trial, did not show any mortality benefit nor 
did it reduce the rate of heart failure hospitalizations�
Early attempts at neprilysin inhibition with the 
hope of raising the levels of natriuretic peptide and 
its activity unmasked another factor that had to be 
considered� Compounds such as racecadotril and 
candoxatrilat, although successful in raising levels 
of ANP, did not produce a sustained hemodynamic 
effect that was desired (14)� It soon became appar-
ent that due to the role that neprilysin also plays in 
Ang II breakdown, lone neprilysin inhibition without 
concurrent inhibition of the RAAS was not likely to 
succeed due to persistent circulating levels of Ang II 
(14)� The vasodilatory effects obtained were offset 
by the vasoconstriction caused by Ang II�
Chemical Structure, Pharmacokinetics 
and Metabolism
Sacubitril/valsartan (LCZ-696) is a combined 
neprilysin inhibitor and angiotensin AT1 receptor 
blocker� Its empirical formula (hemipentahydrate) 
is C48H55N6O8Na3 2�5 H2O with a molecular mass of 
957�99� The chemical structure is shown in Figure 1�
Sacubitril is a prodrug and the therapeutic effect of 
sacubitril/valsartan is partly achieved via the action 
of the active metabolite of sacubitril, LBQ-657, which 
inhibits neprilysin� At the same time, blockade of the 
Ang II type 1 (AT1) receptor is provided by the action 
of valsartan and it is this concurrent inhibition of 
both pathways that leads to sacubitril/valsartan’s 
overall therapeutic effect (Fig� 2)�
In a study involving 30 selected patients who were 
given the drug in dosages of 100 mg twice daily 
and 200 mg twice daily, plasma concentrations 
of sacubitril, LBQ-657 (sacubitrilat) and valsartan 
increased rapidly and reached plasma concen-
tration within 0�5, 2�5 and 2 h, respectively (15)� 
Cmax and AUC0-12h for sacubitril and LBQ-657 were 
dose-proportional while for valsartan they were 
less so (15)�
Levels of cyclic guanosine monophosphate (cGMP) 
in the urine and plasma as well as levels of ANP in the 
urine were increased in volunteer subjects� Plasma 
renin markers (plasma renin activity, plasma renin 
concentration) were significantly raised during the 
same period� All of these biomarker trends reflect 
neprilysin inhibition and AT1 receptor blockade (15)� 
Figure 1. Chemical structure of sacubitril/valsartan (LCZ-696)�
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Oral bioavailability is estimated to be around at least 
60%� The terminal half-lives of sacubitril, LBQ-657 
and valsartan have been 1�3, 12 and 21 h, respec-
tively (16)� Steady state levels of sacubitril/valsartan 
with a twice-daily dosing regimen are achieved in 3 
days�
Drug elimination is primarily through renal excre-
tion in the form of the active metabolite LBQ-657� 
An estimated 51-68% is excreted through the urine 
while the remainder is excreted through the feces� 
In vivo studies have demonstrated a low risk of 
inhibiting or inducing the cytochrome P450 (CYP) 
enzymes (16)�
Clinical Studies
PARAMOUNT and PARADIGM-HF
The PARAMOUNT study was a phase II, randomized, 
parallel-group, double-blind multicenter trial in 
patients with New York Heart Association (NYHA) 
class II-III symptoms and heart failure with pre-
served ejection fraction (HFpEF)� This was defined 
as having an ejection fraction of more than 45% 
and NT-proBNP > 400 pg/mL (17)� Patients were 
assigned to receive either sacubitril/valsartan, 
titrated to 200 mg twice daily or valsartan, titrated 
to 160 mg twice daily� The trial was designed to 
investigate the safety and efficacy of sacubitril/
valsartan in patients with HFpEF� The primary 
endpoint was change from baseline in the levels 
of NT-proBNP at 12 weeks (17)� Secondary end-
points measured were echocardiographic parame-
ters, blood pressure, NYHA class and quality of life 
as measured by the Kansas City Cardiomyopathy 
Questionnaire (KCCQ) (17, 18)� Although the initial 
change in NT-proBNP was significant at 12 weeks in 
the sacubitril/valsartan group, this was no longer 
significant at 36 weeks� Despite an improvement 
in NYHA class, there was no significant difference 
in echocardiographic parameters or quality of life 
(17, 18)� Whether some of these positive signals 
will translate into improved outcomes is unclear 
and currently a prospective trial (PARAGON-HF) is 
ongoing to address this question (ClinicalTrials�gov 
Identifier NCT01920711)�
The PARADIGM-HF trial was another trial designed 
to compare the effects of sacubitril/valsartan to 
those of enalapril in patients with HFrEF� It was a 
double-blind trial and 8,442 patients with NYHA 
class II-IV symptoms and an ejection fraction of at 
least 40% were randomized to either sacubitril/ 
valsartan (at a dose of 200 mg daily) or enalapril (at 
Figure 2. Mechanism of action for sacubitril/valsartan (LCZ-696)�
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a dose of 10 mg twice daily), in addition to recom-
mended therapy (19)�
The primary outcome was a composite of death from 
a cardiovascular cause or hospitalization for heart 
failure (19)� There was an overwhelming mortality 
benefit in the sacubitril/valsartan arm and the trial 
had to be stopped early� The primary outcome had 
occurred in 914 (21�8%) of the patients who received 
sacubitril/valsartan, compared to 1,117 (26�5%) of 
the patients who received enalapril (hazard ratio 
= 0�80 in the sacubitril/valsartan group; 95% confi-
dence interval: 0�73 to 0�87; P < 0�001) (19)�
The most frequent adverse effect seen in the study 
was hypotension, which was more common in 
patients given sacubitril/valsartan� However, this 
did not cause a significant number of patients to 
discontinue the drug as there were only 36 patients 
(0�9%) in the sacubitril/valsartan group and 29 
(0�7%) in the enalapril group who had to discontinue 
the drug because of hypotension�
Hypotension is a risk factor for renal failure and 
although this has been a concern, the study find-
ings suggest lower incidents of clinically relevant 
increases in serum creatinine and drug discon-
tinuation in the sacubitril/valsartan arm (18, 19)� 
Similarly, event rates for angioedema were reas-
suringly low, unlike findings from earlier studies of 
neprilysin inhibition such as the OVERTURE study 
where angioedema was found to be higher in the 
omapatrilat group compared to the enalapril group 
(20)� This result is likely attributed to sacubitril/
valsartan not inhibiting ACE or aminopeptidase P, 
two enzymes known to be involved in bradykinin 
breakdown, which was the Achilles’ heel of oma-
patrilat (18, 19)� A similarly notable observation is 
the incidence of hyperkalemia that occurred more 
frequently in the enalapril group where 236 (5�6%) 
patients had a serum potassium of more than 
6 mmol/L compared to the sacubitril/valsartan 
group which only saw 181 (4�3%) patients with the 
same adverse side effect (19)�
What is also worth noting in the PARADIGM-HF study 
is the higher proportion of patients on contem-
porary heart failure therapy� This is in contrast to 
earlier heart failure trials and reflects modern 
day practice� More than 90% of patients were on a 
β-blocker, at least 80% were on a diuretic, and more 
than half were on a mineralocorticoid antagonist 
(19)� Despite what is perceived to be optimum med-
ical therapy, sacubitril/valsartan still offered signif-
icant mortality benefit above and beyond standard 
treatment� These findings are compelling and have 
indeed begun to change the landscape of chronic 
heart failure treatment�
The Future: PARADISE-MI
Currently, sacubitril/valsartan is indicated for 
patients who remain symptomatic despite being on 
optimum heart failure therapy, including an opti-
mum dose of an ACE inhibitor� This can be defined 
as having a hospital admission for heart failure exac-
erbation or worsening symptoms in an outpatient 
setting�
The next logical step, however, is to investigate 
whether sacubitril/valsartan could be used at an 
earlier stage, prior to the use of an ACE inhibitor in 
patients who have suffered a myocardial infarc-
tion and therefore are at risk of heart failure� The 
early hemodynamic changes postinfarction result-
ing from stimulation of the sympathetic nervous 
system, RAAS, and release of ANP and BNP often 
leads to deleterious left ventricular remodeling� 
Sacubitril/valsartan has already proven itself to be 
more influential than conventional ACE inhibitors in 
altering the course of chronic heart failure patients� 
It is hoped that earlier intervention in the myocar-
dial remodeling process postinfarction will translate 
into better outcomes for patients�
The Prospective ARNI vs ACE Inhibitor Trial to 
DetermIne Superiority in Reducing Heart Failure 
Events After MI (PARADISE-MI) aims to answer this 
clinical question and is currently recruiting and the 
study is expected to be completed in 2020� It is a mul-
ticenter, randomized, double-blind, controlled trial 
and will evaluate the effect of sacubitril/valsartan 
titrated to a target dose of 200 mg twice daily against 
ramipril titrated to a target dose of 5 mg twice daily 
in patients following a myocardial infarction, on top 
of standard postmyocardial infarction treatment�
Primary outcome will be a composite endpoint of 
cardiovascular death, heart failure hospitaliza-
tion and outpatient heart failure (time-to-first-
event analysis) with evidence of left ventricular 
systolic impairment or pulmonary congestion 
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with no previous history of chronic heart failure 
(ClinicalTrials�gov Identifier NCT02924727)� With 
such promising results from PARADIGM-HF, it is 
hoped that PARADISE-MI will further offer clinicians 
treatment options to reduce the incidence of heart 
failure in postmyocardial infarction patients and 
reduce cardiovascular mortality�
Conclusions
Sacubitril/valsartan is opening up a wealth of oppor-
tunities for patients with HFrEF� In an area where 
there has been limited pharmacological advances in 
the last 10 years, this is a game changer and a much 
welcomed addition to contemporary heart failure 
therapy� The clinical data is robust, and the drug 
has been proven to offer marked mortality benefit 
over ACE inhibitors in chronic heart failure patients 
with a good drug safety profile� Its use in patients 
with HFpEF is unclear as phase II trial data to date 
have not shown significant difference with standard 
therapy�
Whether sacubitril/valsartan will change outcomes 
in the postmyocardial infarction cohort who are at 
risk of developing heart failure remains to be seen, 
and results from PARADISE-MI will be awaited by the 
global cardiology community with great interest�
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